SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

Abroad (travel likely)RecruitingPHASE2

Conditions

Lupus Nephritis · Chronic Kidney Diseases

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Queen Mary Hospital, Hong Kong, Hong Kong
Contact: Study coordinator (Desmond Yap, MD (HK) · desmondy@hku.hk · 85222554385

Study leads

Desmond Yap, MD (HK)
Principal Investigator
The University of Hong Kong

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

Kidney Diseases · Kidney Failure, Chronic · Diabetic Nephropathy

Abroad (travel likely)Recruiting

New York, United States

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

Lupus Nephritis

Abroad (travel likely)RecruitingPHASE2

Syracuse, United States · San Antonio, United States

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

SLE · Systemic Lupus Erythematosus (SLE) · CAR T Cell

Abroad (travel likely)RecruitingPHASE1, PHASE2

Philadelphia, United States

SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus

REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS · Lupus Nephritis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shenzhen, China